-
1.发明公开METHODS AND COMPOSITIONS USEFUL FOR MODULATION OF ANGIOGENESIS USING PROTEIN KINASE RAF AND RAS 审中-公开方法和连接基于蛋白激酶Raf和RAS调制血管生成
公开(公告)号：EP1210099A1
公开(公告)日：2002-06-05
申请号：EP00955423.9
申请日：2000-08-11
发明人： HOOD, John , ELICEIRI, Brian , CHERESH, David, A.
摘要： The present invention describes methods for modulating angiogenesis in tissues using Raf and/or Ras protein, modified Raf or Ras protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Raf and/or Ras protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Raf and/or Ras protein, or nucleic acids encoding therefor. The invention also describes the use of gene delivery systems for providing nucleic acids encoding for the Raf or Ras protein, or modified forms thereof.
-
公开(公告)号：EP1250155B1
公开(公告)日：2008-04-16
申请号：EP00990365.9
申请日：2000-12-22
CPC分类号： A61K38/45 , A01K67/0271 , A61K48/00
摘要： The present invention describes methods for modulating vascular permeability (VP) in tissues using Src or modified Src protein, Yes protein or modified Yes protein, Src family tyrosine kinase protein inhibitors, and nucleic acids capable of expression of Src or modified Src protein, Yes protein or modified Yes protein, and Src family tyrosine kinase protein inhibitors, or mixtures thereof. The invention also describes methods for inhibiting VP using an inactive Src or Yes protein or a mixture thereof, or CSK protein or modified CSK protein, or nucleic acids encoding therefor, or by using chemical Src family tyrosine kinase inhibitors such as PP1, PP2, PD173955, AGL1872, PD162531, Radicicol R2146, and Geldanamycin, or for potentiating VP using an active Src or Yes protein or a mixture thereof, or nucleic acids encoding therefor. Related compositions and articles of manufacture are also disclosed.
-
公开(公告)号：EP1250155A1
公开(公告)日：2002-10-23
申请号：EP00990365.9
申请日：2000-12-22
CPC分类号： A61K38/45 , A01K67/0271 , A61K48/00
摘要： The present invention describes methods for modulating vascular permeability (VP) in tissues using Src or modified Src protein, Yes protein or modified Yes protein, Src family tyrosine kinase protein inhibitors, and nucleic acids capable of expression of Src or modified Src protein, Yes protein or modified Yes protein, and Src family tyrosine kinase protein inhibitors, or mixtures thereof. The invention also describes methods for inhibiting VP using an inactive Src or Yes protein or a mixture thereof, or CSK protein or modified CSK protein, or nucleic acids encoding therefor, or by using chemical Src family tyrosine kinase inhibitors such as PP1, PP2, PD173955, AGL1872, PD162531, Radicicol R2146, and Geldanamycin, or for potentiating VP using an active Src or Yes protein or a mixture thereof, or nucleic acids encoding therefor. Related compositions and articles of manufacture are also disclosed.
-
公开(公告)号：EP1744735A2
公开(公告)日：2007-01-24
申请号：EP05732001.2
申请日：2005-03-15
发明人： CHERESH, David A. , PAUL, Robert , ELICEIRI, Brian
IPC分类号： A61K31/00
CPC分类号： A61K31/00 , A61K31/519
摘要： Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. In a particularly preferred embodiment, the Src family tyrosine kinase inhibitor is an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.
-
公开(公告)号：EP1567160A2
公开(公告)日：2005-08-31
申请号：EP03790028.9
申请日：2003-11-18
IPC分类号： A61K31/519 , A61K38/45
CPC分类号： A01K67/0271 , A61K31/519 , A61K38/45 , A61K48/00
摘要： Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.
-
6.发明授权
公开(公告)号：EP1082415B1
公开(公告)日：2011-04-20
申请号：EP99924535.0
申请日：1999-05-28
CPC分类号： C12N9/12 , A61K38/00 , A61K48/00 , C12N2799/021
摘要： The present invention describes methods for modulating angiogenesis in tissues using Src protein, modified Src protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Src protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Src protein, or nucleic acids encoding therefor. The invention also describes the use of gene delivery systems for providing nucleic acids encoding for the Src protein, or modified forms thereof.
-
7.发明公开METHODS AND COMPOSITIONS USEFUL FOR MODULATION OF ANGIOGENESIS USING TYROSINE KINASE SRC 有权调制血管生成的方法酪氨酸激酶SRC的方式
公开(公告)号：EP1082415A1
公开(公告)日：2001-03-14
申请号：EP99924535.0
申请日：1999-05-28
申请人： The Scripps Research Institute , THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
IPC分类号： C12N9/00
CPC分类号： C12N9/12 , A61K38/00 , A61K48/00 , C12N2799/021
摘要： The present invention describes methods for modulating angiogenesis in tissues using Src protein, modified Src protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Src protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Src protein, or nucleic acids encoding therefor. The invention also describes the use of gene delivery systems for providing nucleic acids encoding for the Src protein, or modified forms thereof.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.013 秒)
